Lanean...
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
BACKGROUND: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-car...
Gorde:
| Argitaratua izan da: | N Engl J Med |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6716603/ https://ncbi.nlm.nih.gov/pubmed/30779531 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1816047 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|